CD109 expression levels in malignant melanoma

Journal of Dermatological Science

Volumn 57, Issue 2, 2010, Pages 140-142

  Ohshima, Yuichiro ^a,b   Yajima, Ichiro ^a   Kumasaka, Mayuko Y ^a   Yanagishita, Takeshi ^a,b   Watanabe, Daisuke ^b   Takahashi, Masahide ^c   Inoue, Yuji ^d   Ihn, Hironobu ^d   Matsumoto, Yoshinari ^b   Kato, Masashi ^a  

^a CHUBU UNIVERSITY   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

CD109; Malignant melanoma; RET

Indexed keywords

BIOLOGICAL MARKER; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PROTEIN CD109; PROTEIN RET; UNCLASSIFIED DRUG;

ANIMAL CELL; BENIGN TUMOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LETTER; MELANOGENESIS; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD; CELL LINE, TUMOR; CELLS, CULTURED; HUMANS; MELANOCYTES; MELANOMA; MICE; NEOPLASM PROTEINS; RNA, MESSENGER; SKIN; SKIN NEOPLASMS; TISSUE DISTRIBUTION;

EID: 74749097708     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.11.004     Document Type: Letter

References (10)

1. Ugurel S., Utikal J., and Becker J.C. Tumor biomarkers in melanoma. Cancer Control 16 (2009) 219-224
2. Yajima I., Kumasaka M., Thang N.D., Yanagishita T., Ohgami N., Kallenberg D., et al. Zinc finger protein 28 as a novel melanoma-related molecule. J Dermatol Sci 55 (2009) 68-70
3. Lin M., Sutherland D.R., Horsfall W., Totty N., Yeo E., Nayar R., et al. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99 (2002) 1683-1691
4. Finnson K.W., Tam B.Y., Liu K., Marcoux A., Lepage P., Roy S., et al. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB 20 (2006) 1525-1527
5. Hashimoto M., Ichihara M., Watanabe T., Kawai K., Koshikawa K., Yuasa N., et al. Expression of CD109 in human cancer. Oncogene 23 (2004) 3716-3720
6. Kato M., Takahashi M., Akhand A.A., Liu W., Dai Y., Shimizu S., et al. Transgenic mouse model for skin malignant melanoma. Oncogene 17 (1998) 1885-1888
7. Kato M., Takeda K., Kawamoto Y., Tsuzuki T., Hossain K., Tamakoshi A., et al. c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 64 (2004) 801-806
8. Kato M., Liu W., Akhand A.A., Dai Y., Ohbayashi M., Tuzuki T., et al. Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I/ret transgenic mouse lines. Oncogene 18 (1999) 837-842
9. Goodall J., Carreira S., Denat L., Kobi D., Davidson I., Nuciforo P., Sturm R.A., et al. Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. Cancer Res 68 (2008) 7788-7794
10. Sato T., Murakumo Y., Hagiwara S., Jijiwa M., Suzuki C., Yatabe Y., et al. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57 (2007) 719-724